| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Cadonilimab Basic information |
| Product Name: | Cadonilimab | | Synonyms: | Cadonilimab;Research Grade Cadonilimab (DHH02221);Research Grade Cadonilimab | | CAS: | 2394841-59-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Cadonilimab Structure]() |
| | Cadonilimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Cadonilimab Usage And Synthesis |
| Uses | Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC)[1][2][3][4]. | | in vivo | Cadonilimab (3.7 MBq, tail i.v., a single dose) modified with 124I largely enriches in the spleen, tumor sites and results in enrichment of PD1/CTLA4 positive immune cells at the tumor sites in humanized mice with MC38-hPD-L1 cell xenografts[4].
| Animal Model: | Normal KM mice and B-hPD1/hCTLA4-MC38-hPD-L1 mice[4] | | Dosage: | 3.7 MBq (Cadonilimab modified with 124I) | | Administration: | tail i.v., a single dose, 2, 24, 96 and 192h post-injection acquired static PET scans | | Result: | Resulted in higher tumor to nontumor (T/NT) ratios and increaseed the standard uptake value (SUV) value at the tumor site modified with 124I in mice. |
| | References | [1] Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884. DOI:10.3390/ph14090884
[2] Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296. DOI:10.1080/19420862.2021.2014296
[3] Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523. DOI:10.3389/fimmu.2023.1188523
[4] Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669. DOI:10.1016/j.biopha.2024.116669 |
| | Cadonilimab Preparation Products And Raw materials |
|